|
1
|
Hoefler H, Kerl H, Rauch HJ and Denk H:
New immunocytochemical observations with diagnostic significance in
cutaneous neuroendocrine carcinoma. Am J Dermatopathol. 6:525–530.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Walsh NM: Primary neuroendocrine (Merkel
cell) carcinoma of the skin: Morphologic diversity and implications
thereof. Hum Pathol. 32:680–689. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Becker JC, Stang A, DeCaprio JA, Cerroni
L, Lebbe C, Veness M and Nghiem P: Merkel cell carcinoma. Nat Rev
Dis Primers. 3:170772017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pavolucci L, Giannini G, Giannoccaro MP,
Foschini MP, Lang B, Avoni P, Tinuper P, Vincent A and Liguori R:
Paraneoplastic cerebellar degeneration and lambert-eaton myasthenia
in a patient with merkel cell carcinoma and voltage-gated calcium
channel antibodies. Muscle Nerve. 56:998–1000. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eggers SD, Salomao DR, Dinapoli RP and
Vernino S: Paraneoplastic and metastatic neurologic complications
of Merkel cell carcinoma. Mayo Clin Proc. 76:327–330. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaufman HL, Russell J, Hamid O, Bhatia S,
Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M,
et al: Avelumab in patients with chemotherapy-refractory metastatic
Merkel cell carcinoma: A multicentre, single-group, open-label,
phase 2 trial. Lancet Oncol. 17:1374–1385. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Collins JM and Gulley JL: Product review:
Avelumab, an anti-PD-L1 antibody. Hum Vaccin Immunother.
15:891–908. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kesner VG, Oh SJ, Dimachkie MM and Barohn
RJ: Lambert-eaton myasthenic syndrome. Neurol Clin. 36:379–394.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O'Neill JH, Murray NM and Newsom-Davis J:
The lambert-eaton myasthenic syndrome. A review of 50 cases. Brain.
111:577–596. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Skeie GO, Apostolski S, Evoli A, Gilhus
NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge
HW, et al: Guidelines for treatment of autoimmune neuromuscular
transmission disorders. Eur J Neurol. 17:893–902. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gustafsson B, Priftakis P, Rubin J, Giraud
G, Ramqvist T and Dalianis T: Human polyomaviruses were not
detected in cerebrospinal fluid of patients with neurological
complications after hematopoietic stem cell transplantation. Future
Virol. 8:809–814. 2013. View Article : Google Scholar
|
|
12
|
Llombart B, Monteagudo C, Lopez-Guerrero
JA, Carda C, Jorda E, Sanmartin O, Almenar S, Molina I, Martín JM
and Llombart-Bosch A: Clinicopathological and immunohistochemical
analysis of 20 cases of Merkel cell carcinoma in search of
prognostic markers. Histopathology. 46:622–634. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kervarrec T, Zaragoza J, Gaboriaud P, Le
Gouge A, Beby-Defaux A, Le Corre Y, Hainaut-Wierzbicka E, Aubin F,
Bens G, Michenet P, et al: Differentiating Merkel cell carcinoma of
lymph nodes without a detectable primary skin tumor from other
metastatic neuroendocrine carcinomas: The ELECTHIP criteria. J Am
Acad Dermatol. 78:964–972. e32018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garcia-Carbonero R, Sorbye H, Baudin E,
Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C,
Anlauf M, Cwikla JB, et al: ENETS consensus guidelines for
high-grade gastroenteropancreatic neuroendocrine tumors and
neuroendocrine carcinomas. Neuroendocrinology. 103:186–194. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kuwamoto S: Recent advances in the biology
of Merkel cell carcinoma. Hum Pathol. 42:1063–1077. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Feng H, Shuda M, Chang Y and Moore PS:
Clonal integration of a polyomavirus in human Merkel cell
carcinoma. Science. 319:1096–1100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sihto H, Kukko H, Koljonen V, Sankila R,
Bohling T and Joensuu H: Clinical factors associated with Merkel
cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer
Inst. 101:938–945. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Duncavage EJ, Le BM, Wang D and Pfeifer
JD: Merkel cell polyomavirus: A specific marker for Merkel cell
carcinoma in histologically similar tumors. Am J Surg Pathol.
33:1771–1777. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ordonez NG: Value of thyroid transcription
factor-1 immunostaining in distinguishing small cell lung
carcinomas from other small cell carcinomas. Am J Surg Pathol.
24:1217–1223. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Taralli S, Sollini M, Milella M, Perotti
G, Filice A, Menga M, Versari A and Rufini V: (18)F-FDG and
(68)Ga-somatostatin analogs PET/CT in patients with Merkel cell
carcinoma: A comparison study. EJNMMI Res. 8:642018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ishida Y: PD-1: Its discovery, involvement
in cancer immunotherapy, and beyond. Cells. 9:13762020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Desch L and Kunstfeld R: Merkel cell
carcinoma: Chemotherapy and emerging new therapeutic options. J
Skin Cancer. 2013:3271502013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dohrn MF, Schone U, Kuppers C, Christen D,
Schulz JB, Gess B and Tauber S: Immunoglobulins to mitigate
paraneoplastic lambert eaton myasthenic syndrome under checkpoint
inhibition in Merkel cell carcinoma. Neurol Res Pract. 2:522020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Agostini A, Merli M, Avallone G, Burzi L,
Mastorino L, Parisi M, Bertuzzo D, Ferrero B, Cerrato M, Badellino
S, et al: Lambert-eaton myasthenic syndrome and paraneoplastic
cerebellar degeneration associated with merkel cell carcinoma with
unknown primary: A case report. Acta Derm Venereol.
101:adv004522021.PubMed/NCBI
|
|
25
|
Nguyen ND, Simmons DB, Bersabe AR,
Duginski TM, Sladky JH, Walton D, Will M and Renshaw JS:
Lambert-Eaton myasthenic syndrome and merkel cell carcinoma. Cutis.
103:E19–E23. 2019.PubMed/NCBI
|
|
26
|
Iyer JG, Parvathaneni K, Bhatia S,
Tarabadkar ES, Blom A, Doumani R, McKenzie J, Asgari MM and Nghiem
P: Paraneoplastic syndromes (PNS) associated with Merkel cell
carcinoma (MCC): A case series of 8 patients highlighting different
clinical manifestations. J Am Acad Dermatol. 75:541–547. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bombelli F, Lispi L, Calabro F, Corsi FM
and Petrucci A: Lambert-Eaton myasthenic syndrome associated to
Merkel cell carcinoma: Report of a case. Neurol Sci. 36:1491–1492.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee JH, Baek SK, Han JJ, Kim HJ, Lee YA,
Yoo D and Maeng CH: Lambert-Eaton myasthenic syndrome (LEMS) in a
patient with lung cancer under treatment with pembrolizumab: A case
study. J Chemother. 13:1–6. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sakaguchi T, Kokubo Y, Furuhashi K,
Nakamura Y, Suzuki Y, Ito K, Fujiwara K, Nishii Y, Taguchi O and
Hataji O: An extensive-stage small-cell lung cancer case with
preexisting lambert-eaton myasthenic syndrome successfully treated
with an immune checkpoint inhibitor. Clin Lung Cancer.
23:e273–e275. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gill AJ, Gandhy S and Lancaster E:
Nivolumab-associated lambert-eaton myasthenic syndrome and
cerebellar dysfunction in a patient with a neuroendocrine tumor.
Muscle Nerve. 63:E18–E21. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kunii E, Owaki S, Yamada K, Yoshihara M,
Yamaba Y, Takakuwa O, Toyoda T and Akita K: Lambert-eaton
myasthenic syndrome caused by atezolizumab in a patient with
small-cell lung cancer. Intern Med. 61:1739–1742. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakatani Y, Tanaka N, Enami T, Minami S,
Okazaki T and Komuta K: Lambert-eaton myasthenic syndrome caused by
nivolumab in a patient with squamous cell lung cancer. Case Rep
Neurol. 10:346–352. 2018. View Article : Google Scholar : PubMed/NCBI
|
